353131 20250717224050.0 10.1016/j.ijrobp.2023.12.042 doi 0360-3016 ISSN 1879-355X ISSN 10.15120/GSI-2024-00796 datacite_doi altmetric:162613288 altmetric pmid:38163521 pmid WOS:001263754200001 WOS GSI-2024-00796 English 610 Salomon, Nadja P:(DE-HGF)0 0 Corresponding author Carbon Ion and Photon Radiation Therapy Show Enhanced Antitumoral Therapeutic Efficacy With Neoantigen RNA-LPX Vaccines in Preclinical Colon Carcinoma Models Amsterdam [u.a.] 2024 Elsevier Science article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1752758698_898618 PUB:(DE-HGF) ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) Personalized liposome-formulated mRNA vaccines (RNA-LPX) are a powerful new tool in cancer immunotherapy. In preclinical tumor models, RNA-LPX vaccines are known to achieve potent results when combined with conventional X-ray radiation therapy (XRT). Densely ionizing radiation used in carbon ion radiation therapy (CIRT) may induce distinct effects in combination with immunotherapy compared with sparsely ionizing X-rays.Within this study, we investigate the potential of CIRT and isoeffective doses of XRT to mediate tumor growth inhibition and survival in murine colon adenocarcinoma models in conjunction with neoantigen (neoAg)-specific RNA-LPX vaccines encoding both major histocompatibility complex (MHC) class I- and class II-restricted tumor-specific neoantigens. We characterize tumor immune infiltrates and antigen-specific T cell responses by flow cytometry and interferon-γ enzyme-linked immunosorbent spot (ELISpot) analyses, respectively.NeoAg RNA-LPX vaccines significantly potentiate radiation therapy-mediated tumor growth inhibition. CIRT and XRT alone marginally prime neoAg-specific T cell responses detected in the tumors but not in the blood or spleens of mice. Infiltration and cytotoxicity of neoAg-specific T cells is strongly driven by RNA-LPX vaccines and is accompanied by reduced expression of the inhibitory markers PD-1 and Tim-3 on these cells. The neoAg RNA-LPX vaccine shows similar overall therapeutic efficacy in combination with both CIRT and XRT, even if the physical radiation dose is lower for carbon ions than for X-rays.We hence conclude that the combination of CIRT and neoAg RNA-LPX vaccines is a promising strategy for the treatment of radioresistant tumors. 633 - Life Sciences – Building Blocks of Life: Structure and Function (POF4-633) G:(DE-HGF)POF4-633 POF4-633 POF IV 0 SUC-GSI-Darmstadt - Strategic university cooperation GSI-TU Darmstadt (SUC-GSI-DA) G:(DE-Ds200)SUC-GSI-DA SUC-GSI-DA 1 FAIR Phase-0 - FAIR Phase-0 Research Program (GSI-FAIR-Phase-0) G:(Ds200)GSI-FAIR-Phase-0 GSI-FAIR-Phase-0 2 Dataset connected to CrossRef, Journals: repository.gsi.de Cancer Vaccines NLM Chemicals Antigens, Neoplasm NLM Chemicals Liposomes NLM Chemicals mRNA Vaccines NLM Chemicals RNA, Messenger NLM Chemicals Animals MeSH Colonic Neoplasms: radiotherapy MeSH Colonic Neoplasms: immunology MeSH Mice MeSH Cancer Vaccines: therapeutic use MeSH Cancer Vaccines: immunology MeSH Antigens, Neoplasm: immunology MeSH Heavy Ion Radiotherapy: methods MeSH Photons: therapeutic use MeSH Female MeSH Adenocarcinoma: radiotherapy MeSH Adenocarcinoma: immunology MeSH Combined Modality Therapy: methods MeSH Liposomes MeSH mRNA Vaccines: therapeutic use MeSH Cell Line, Tumor MeSH Immunotherapy: methods MeSH RNA, Messenger MeSH Mice, Inbred C57BL MeSH HTM SBio08_Salomon: Combined carbon ion radiotherapy and cancer vaccines in a subcutaneous murine MC38 adenocarcinoma model (POF3-315; HTM ) EXP:(DE-Ds200)HTM-20200803 EXP:(DE-Ds200)SBio08_Salomon-20200803 EXP:(DE-Ds200)SBio08_Salomon-20200803 0 Helm, Alexander P:(DE-Ds200)OR3001 1 gsi Selmi, Abderaouf P:(DE-HGF)0 2 Fournier, Claudia P:(DE-Ds200)OR0311 3 gsi Diken, Mustafa P:(DE-HGF)0 4 Schrörs, Barbara P:(DE-HGF)0 5 Scholz, Michael P:(DE-Ds200)OR1138 6 gsi Kreiter, Sebastian P:(DE-HGF)0 7 Durante, Marco P:(DE-Ds200)OR2413 8 gsi Vascotto, Fulvia P:(DE-HGF)0 9 10.1016/j.ijrobp.2023.12.042 Vol. 119, no. 3, p. 936 - 945 PERI:(DE-600)1500486-7 3 936 - 945 International journal of radiation oncology, biology, physics 119 2024 0360-3016 http://repository.gsi.de/record/353131/files/1-s2.0-S0360301623083141-main.pdf OpenAccess http://repository.gsi.de/record/353131/files/1-s2.0-S0360301623083141-main.pdf?subformat=pdfa pdfa OpenAccess oai:repository.gsi.de:353131 openaire open_access VDB driver dnbdelivery GSI Helmholtzzentrum für Schwerionenforschung GmbH I:(DE-Ds200)20121206GSI GSI 1 P:(DE-Ds200)OR3001 GSI Helmholtzzentrum für Schwerionenforschung GmbH I:(DE-Ds200)20121206GSI GSI 3 P:(DE-Ds200)OR0311 GSI Helmholtzzentrum für Schwerionenforschung GmbH I:(DE-Ds200)20121206GSI GSI 6 P:(DE-Ds200)OR1138 GSI Helmholtzzentrum für Schwerionenforschung GmbH I:(DE-Ds200)20121206GSI GSI 8 P:(DE-Ds200)OR2413 DE-HGF Forschungsbereich Materie Von Materie zu Materialien und Leben G:(DE-HGF)POF4-630 G:(DE-HGF)POF4-633 G:(DE-HGF)POF4 G:(DE-HGF)POF4-600 G:(DE-HGF)POF Life Sciences – Building Blocks of Life: Structure and Function 0 2024 DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection 2023-08-24 DBCoverage StatID:(DE-HGF)0160 StatID Essential Science Indicators 2023-08-24 DBCoverage StatID:(DE-HGF)1050 StatID BIOSIS Previews 2023-08-24 DBCoverage StatID:(DE-HGF)1190 StatID Biological Abstracts 2023-08-24 DBCoverage StatID:(DE-HGF)0600 StatID Ebsco Academic Search 2023-08-24 JCR StatID:(DE-HGF)0100 StatID INT J RADIAT ONCOL : 2022 2023-08-24 WoS StatID:(DE-HGF)0113 StatID Science Citation Index Expanded 2023-08-24 OpenAccess StatID:(DE-HGF)0510 StatID Creative Commons Attribution CC BY 4.0 LIC:(DE-HGF)CCBY4 HGFVOC Peer Review StatID:(DE-HGF)0030 StatID ASC 2023-08-24 IF >= 5 StatID:(DE-HGF)9905 StatID INT J RADIAT ONCOL : 2022 2023-08-24 DBCoverage StatID:(DE-HGF)0300 StatID Medline 2023-08-24 DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS 2023-08-24 DBCoverage StatID:(DE-HGF)1110 StatID Current Contents - Clinical Medicine 2023-08-24 Nationallizenz StatID:(DE-HGF)0420 StatID 2023-08-24 ger DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List 2023-08-24 yes I:(DE-Ds200)BIO-20160831OR354 BIO Biophysik 0 I:(DE-Ds200)Coll-FAIR-BIO BIO@FAIR Collaboration FAIR: BIO 1 journal VDB I:(DE-Ds200)BIO-20160831OR354 I:(DE-Ds200)Coll-FAIR-BIO UNRESTRICTED FullTexts